WX-UK1 + capecitabine

WX-UK1 + capecitabine is an investigational combination therapy studied primarily for advanced malignancies. WX-UK1 is a 3-amidinophenylalanine-based small molecule inhibitor of serine proteases, specifically targeting the urokinase plasminogen activator (uPA) system, which plays a key role in tumor invasion and metastasis. Capecitabine is an oral prodrug of 5-fluorouracil (5-FU), widely used as chemotherapy for various cancers including colon and breast cancer. The combination has been evaluated in phase I clinical trials to assess safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors. Early studies indicate that the combination is generally well tolerated with some evidence of antitumor activity[3][4][5][6].